This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Atomoxetine-Associated Hemospermia: A Case Report

Y. Pritham Raj, MD

Published: July 31, 2008

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Atomoxetine is the only nonstimulant medicationapproved by the U.S. Food and Drug Administration for thetreatment of attention-deficit/hyperactivity disorder (ADHD) inchildren, adolescents, and adults. Since its approval in 2002, ithas been widely prescribed and has been associated with a lowoverall incidence of adverse effects. The 4 most common adverseeffects include dry mouth, insomnia, nausea, and erectiledysfunction. The following case report describes a novel adverseeffect associated with atomoxetine—hemospermia.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 69

Quick Links: Anxiety , Anxiolytics

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...